








Transfer #4: Confirmation of \$50.2M payment for Q3 2014 federal tax from BR Holdings Associates L.P. to the US Treasury on behalf of Beacon Company.











AlixPartners

Selection 11 Purdue Tax Distributions (2016)


Selection 11 - Tax Distribution for estimated federal tax payment, Q1 2016




¹ State and other federal tax payments identified in Purdue's Internal Distribution Analysis and SAP General Ledger detail.


We are unable to determine from the books and records maintained by Purdue whether Rosebay Medical Company L.P. used the distributions to make tax-related payments to the appropriate taxing authorities.










Transfer #3: Authorization for \$10.3M payment from BR Holdings Associates L.P. to Rosebay Medical Company L.P. for Q1 2016 estimated federal tax.






Transfer #3: Q1 2016 estimated federal tax for Rosebay Medical Company L.P.










Transfer #4: Confirmation of \$10.3M 1Q16 Federal tax payment from BR Holdings Associates L.P. to US Treasury on behalf of Beacon Company.

YOUR REF: ATS OF 16/03/30




Transfer #1: \$29.9M transfer from Purdue Pharma L.P. to Purdue Holdings L.P.




AlixPartners

Selection 12 Purdue Tax Distributions (2015)












Transfer #1: Authorization for \$6.8M payment from Purdue Pharma L.P. to Rosebay Medical Company L.P. for Q3 2015 estimated Connecticut state tax.










Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)



Selection 12 – Tax Distribution for estimated Connecticut state tax, Q3 2015 (cont'd)






Exhibit F - Rhodes Cash Distributions Tracing Analysis

Rhodes Cash Distributions Tracing Analysis - Objectives

Objective

1. Trace Rhodes Cash Distributions identified in Rhodes's SAP accounts payable ledger to the available third-party bank statements in order to validate if the distributions amounts, posting/transaction dates, payee/beneficiary names and payor entities were consistent and/or similar in both sources of information.

Procedures Performed

- 1. Determined time period and entities to review based on Rhodes and Purdue's Internal Distribution Analysis and our reconciliation work. Bank statements were available for July 2014 onwards unless specifically requested from storage by TXP.
- 2. Reviewed bank statements to determine account holder entity name and time period represented.
- 3. Each Rhodes Cash Distribution identified in Purdue's SAP accounts payable ledger was compared to the available bank statements in order to find a match by payor entity, payee name, posting/transaction date and amount.
- 4. Certain transactions were assumed to be matches even if certain criteria were not an exact match. For example, if a distribution amount matched, but the payee name was not included in the bank statement and the posting date was within 60 days (before or after) of the transaction date included on the bank statement, then the distribution was generally considered to be a match.
 - If any of the criteria were not a match, the discrepancy was noted.
 - For payee name mismatches, the most common reason was that the bank statement did not include a payee name.

Rhodes Cash Distributions Tracing Analysis - Sources Relied Upon

The following sources of information were accessed and reviewed from Purdue, Rhodes and TXP:

- 1. Cash Distributions identified in Rhodes's SAP accounts payable ledger; and
- 2. Bank statements for Rhodes and Affiliated Entities from the below periods highlighted in green:

Coventry Technologies L.P. (Company #230)												
Bank Statement Periods Received												<u>ed</u>
	Q1		Q2			Q3			Q4			
Year	J	F	М	A	М	J	J	Α	S	0	N	D
2014												
2015												
2016												
2017												
2018												

SVC Pharma L.P. (Company #507)												
Bank Statement Periods Received												<u>ed</u>
	Q1		Q2			Q3			Q4			
Year	J	F	М	Α	М	J	J	Α	S	0	N	D
2014												
2015												
2016												
2017												
2018												

Based upon on the tracing work performed on the Rhodes Cash Distributions recorded in the SAP accounts payable ledger to the available third-party bank statements, we have the following observations:

1. The available third-party bank statements included 75 transactions totaling \$53.28 million, of which matches between the two sources of information (SAP accounts payable ledger and Bank Statements) were identified for 75 transactions (100% of total) totaling \$53.28 million (100% of total).

	Payabl	e Le	ns in SAP Accounts edger within Bank ment periods	Accou	Transactions in SAP Accounts Payable Ledger Matched to Bank Statements				
Company Name (Company #)	# Trx		\$ Amount	# Trx		\$ Amount			
Coventry Technologies L.P. (Company #230)	63	\$	52,644,200	63	\$	52,644,200			
SVC Pharma L.P. (Company #507)	12	\$	630,882	12	\$	630,882			
Rhodes Technologies (Company #227)	_	\$	-	_	\$	-			
Rhodes Technologies Inc. (Company #247)	_	\$	-	_	\$	-			
Rhodes Pharmaceuticals LP (Company #250)	_	\$	-	_	\$	-			
Rhodes Pharmaceuticals Inc. (Company #251)	_	\$	-	_	\$	-			
	75	\$	53,275,082	75	\$	53,275,082			
As % of Transactions within Bank Statement periods	100%		100%	100%		100%			

2. For Coventry Technologies L.P. (Entity #230):

Periods for which statements are available:	Jul. 2014 - Dec. 2018						
Number of transactions in SAP accounts payable ledger within available bank statement periods:	63 – \$52.6m						
Number of transactions matched to bank statements (and as % of total for available statement periods):	63 <i>(100%)</i> – \$52.6m <i>(100%)</i>						
Number of exact matches (payee, amount and date):	14 – \$6.49m						
Number of payee and amount matches with close	27 - \$44.96m						
posting date match ¹ :	 2 payments to Rosebay Medical Company LP totaling \$14.65m were combined into a single transaction in the bank statement 						
Number of amount matches with close posting date	22 - \$1.19m						
match ¹ (no payee name listed in bank statement):	All are checks for tax-related payments						

¹ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

3. For SVC Pharma L.P. (Entity #507):

. I a contrata de la companya de la
Aug. 2014 - Dec. 2018
21 – \$1.17m
12 – \$631k
12 <i>(100%)</i> – \$631k <i>(100%)</i>
0
2 – \$186k
10 – \$445k • All are checks recorded in SAP as payable to Comptroller of Maryland

 $^{^{1}}$ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

4. For Rhodes Technologies (Entity #227):

Periods for which statements are available:	Jul. 2014 – Dec. 2018
Number of transactions in SAP accounts payable ledger within available bank statement periods:	0
Number of transactions matched to bank statements:	0
Number of exact matches (payee, amount and date):	n/a
Number of payee and amount matches with close posting date match ¹ :	n/a
Number of amount matches with close posting date match ¹ (no payee name listed in bank statement):	n/a

¹ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

5. For Rhodes Technologies Inc. (Entity #247):

Periods for which statements are available:	Aug. 2014 - Dec. 2018
Number of transactions in SAP accounts payable ledger within available bank statement periods:	0
Number of transactions matched to bank statements:	0
Number of exact matches (payee, amount and date):	n/a
Number of payee and amount matches with close posting date match ¹ :	n/a
Number of amount matches with close posting date match ¹ (no payee name listed in bank statement):	n/a

¹ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

6. For Rhodes Pharmaceuticals L.P. (Entity #250):

Periods for which statements are available:	Aug. 2014 – Dec. 2018
Number of transactions in SAP accounts payable ledger within available bank statement periods:	0
Number of transactions matched to bank statements:	0
Number of exact matches (payee, amount and date):	n/a
Number of payee and amount matches with close posting date match ¹ :	n/a
Number of amount matches with close posting date match ¹ (no payee name listed in bank statement):	n/a


¹ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

7. For Rhodes Pharmaceuticals Inc. (Entity #251):

Periods for which statements are available:	Aug. 2014 – Dec. 2018
Number of transactions in SAP accounts payable ledger within available bank statement periods:	0
Number of transactions matched to bank statements:	0
Number of exact matches (payee, amount and date):	n/a
Number of payee and amount matches with close posting date match ¹ :	n/a
Number of amount matches with close posting date match ¹ (no payee name listed in bank statement):	n/a

¹ SAP accounts payable ledger posting date considered a match if within +/- 60 days of bank statement transaction date.

8. Statements for the following entities were provided, but no transactions were identified in the SAP accounts payable ledger:



Rhodes Technologies Inc. (Company #247)												
	Bank Statement Periods Received											
	Q1		Q2				Q3		Q4			
Year	J	F	М	Α	М	J	J	Α	S	0	N	D
2014												
2015												
2016												
2017												
2018												

Rhodes Phar					i LF me							
	Q1			Q2			Q3			Q4		
Year	J	F	М	Α	М	J	J	Α	S	0	N	D
2014												
2015												
2016												
2017												
2018												

Rhodes Pharmaceuticals Inc. (Company #251) Bank Statement Periods Received												
	Q1			Q2				Q3		Q4		
Year	J	F	М	Α	М	J	J	Α	S	0	N	D
2014												
2015												
2016												
2017												
2018												

Rhodes Cash Distributions Flow of Funds Analysis

Flow of Funds Analysis – Cash Distribution and Capital Contribution Testing Selections

As illustrated in this section of the Cash Distribution and Capital Contributions Analysis, we performed a flow of funds analysis on each classification of Cash Distributions (Non-Tax and Tax) made ("Rhodes Cash Distribution Testing Selections") and Capital Contributions received ("Rhodes Capital Contributions Testing Selections") by Rhodes (collectively referred to as the "Rhodes Cash Distribution and Capital Contribution Testing Selections"):

Rhodes Cash Distribution Testing Selections

- Selection 1 Non-Tax Cash Distribution from Rhodes Technologies to Beacon Company and Rosebay Medical Company L.P., December 2011
- Selection 2 Tax Distribution for Estimated Federal Tax Payment, Q4 2014

Rhodes Capital Contribution Testing Selections

- Selection 1 Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012
- **Selection 2** Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, May 2013
- **Selection 3** Capital Contribution Received by Rhodes Pharmaceuticals L.P. from Purdue Pharma L.P. through Affiliated Entities, October/November 2013


Rhodes Flow of Funds Analysis – Observations and Findings

The following summary of observations and findings is based upon our review and analysis of various sources of information that we obtained from Rhodes related to the Rhodes Cash Distribution and Capital Contribution Testing Selections:


- 1. Rhodes Cash Distribution Testing Selection 1 was classified by Rhodes as a Non-Tax Cash Distribution that flowed from Rhodes Technologies up to and through Coventry Technologies L.P. and then from Coventry Technologies L.P. to Beacon Company and Rosebay Medical Company L.P.
 - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Non-Tax Cash Distributions made by Rhodes.
- 2. Rhodes Cash Distribution Testing Selection 2 was classified by Rhodes as a Tax Distribution that flowed from Coventry Technologies L.P. to Rosebay Medical Company L.P., Beacon Company and the United States Treasury and such classification is consistent with the documentation supporting this transaction.¹
 - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Tax Distributions made by Rhodes.
- 3. Rhodes Capital Contribution Testing Selections 1 through 3 flowed from Purdue Pharma L.P. up to PRA L.P. and through other holdings companies, and then to Beacon Company and Rosebay Medical Company L.P., which made contributions to Rhodes Technologies or Rhodes Pharmaceuticals L.P. through Coventry Technologies L.P.
 - It is our understanding from Rhodes that this flow of funds pattern is generally consistent with the other Capital Contributions received by Rhodes.
- 4. Rhodes's accounting for the Rhodes Cash Distribution and Capital Contribution Testing Selections flow of funds is consistent with the available written approval and authorization documents supporting these transactions.
- 5. For the Rhodes Cash Distribution Testing Selections, the payee/beneficiary name recorded in Rhodes's accounts payable detail of the SAP general ledger system matches the payee/beneficiary name reported in Rhodes's Internal Distribution Analysis.


Rhodes Cash Distribution Testing Selections


Selection 1 Rhodes Non-Tax Cash Distributions (2011)




¹ For consistency with PPLP's classification of Non-Tax Cash Distributions, this Non-Tax Cash Distribution by Rhodes that flowed up to Beacon Company and Rosebay Medical L.P. has been treated as a US Partner Cash Distribution in the Cash Distributions Analysis.










Selection 2 Rhodes Tax Distribution (2014)








Doc.Type : KR	(Vendor invoice) Normal	documen	t		
Doc. Number	1900000203	Company	Code	230	Fiscal Year	2014
Doc. Date	12/08/2014	Posting	Date	12/12/2014	Period	12
Calculate Tax						
Ref.Doc.	120814E					
Doc. Currency	USD					
_						

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order I	Тx	Amount	Text
1	31	1016497	ROSEBAY MEDICAL COMP		GEN			14,500,000.00	4QTR 2014 FEDERAL ESTIMATED TAX PAYMENT
2	40	302027	Capital #27 Distrib.		GEN			14,500,000.00	4QTR 2014 FEDERAL ESTIMATED TAX PAYMENT


Transfer #1: \$14,500,000 transfer from Coventry Technologies L.P. to Rosebay Medical Company L.P.









Transfer #1: Q4 2014 federal tax payment of \$14,500,000 for Rosebay Medical Company L.P.








Q4 2014 (PROPERTOR WHITE MIDENSHIPS HE RELIES IN RECURRING WIRE X STANDARD WIRE ACH WIRE FOREIGN WIRE DIRECT DEBIT "FOR" ACCOUNTS PAYABLE Payer Bank Acct Name: JPMorganChase USE ONLY Coverny Technologies LP SAP PAYMENT DUE DATE FROM CO. NAME Beacon Company PAYER VENDOR NAME: STREET ADDRESS: SAF VENDOR NUMBERS CITY, STATE, ZIP. RECIPIENT BANK NAME: JPMorgus Private Benk INVOICE NO. 120 NO. CITY, STATE, OP ACCOUNT NUMBER Transfer #3: 04 2014 federal SWIFT CODE: CHASUESS AR DOCUMENT NUMBERS ISAN NUMBER: tax payment of \$1,267,783 for REQUESTED BY: Sue Kowalski Beacon Company. NOTE: BANKING INSTRUCTIONS MUST BE ATTACHED TO EACH WIRE SUBMISSION 1,267,783.00 TOTAL WIRE TRANSFER AMOUNT: 4Q14 Federal Estimated Payment - 3.8% Medicaro Tax Conta/GL ExpensesAcet/Cost Contar/Min/s/Project 1,267,783.00 239-302026-0000000 SSA, Deale (Capital #26-Distributions-Beacon) GAL DIAM. 1,267,783.00 NOTE: 1) Were Transfer Amounts \$100,000 or loss do not require an authorise alg Signature Required \$103,000.01 up to \$550,000 2nd Signature Regularid \$500,000.01 up to \$155M \$1,000,000.01 and shows, one of the signary must be: |(Group II): >\$1MM - Edward Makery INCITIE. Both Groups of "A" Eighers are authorized to sign up to \$000,000 simply (article includes Reymond Sathler), and jointly (tern "A" argumen) \$600,000,01 on as \$100.00 THE ASURY USE ONLY Last Revision: 16/2671

Source: Purdue Tax Department estimate of federal tax payment

Rhodes Capital Contribution Testing Selections

Selection 1 Rhodes Capital Contribution (2012)

Selection 1 – Capital Contribution Received by Rhodes
Technologies from Purdue Pharma L.P. through Affiliated Entities,



Selection 1 – Capital Contribution Received by Rhodes Technologies from Purdue Pharma L.P. through Affiliated Entities, April 2012

